REGENTIS BIOMATERIALS LTD. (RGNT) Form 6-K — Oct 13, 2026
Regentis Biomaterials (NYSE American: RGNT) reported strong surgeon interest in GelrinC, its CE Mark-approved cell-free hydrogel knee cartilage implant, at the 8th ICRS Summit in Porto, Portugal held October 8-10, 2026. CEO Ehud Geller said the engagement reflects growing awareness of GelrinC as the company expands its European Centers of Excellence network to support surgeon training and commercialization. GelrinC showed approximately 100% greater improvement in KOOS scores versus historical microfracture controls at two years, and the company's FDA pivotal Phase III trial has completed over 50% enrollment, targeting a U.S.
Key figures
- Procedure duration minutes
- 10
- Fda pivotal trial enrollment
- over 50% complete
- Functional improvement duration years
- more than 5 years
- Koos score improvement vs microfracture
- approximately 100% greater at two years
- Us annual cartilage knee repair market cases
- 470000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.